Available for eligible patients who are uninsured or cannot afford medication.
*Terms & Conditions may apply.
Complete the RUBRACA Enrollment and Comprehensive Support Form
Your patients may benefit from additional support such as co-pay and coverage programs to help them pay for treatment.
Enroll online
Patients can complete the form online, provide consent, and access their co-pay ID. Prescribers can also input patient information in the access portal.
Download and fax the form
Once your patient has enrolled, a pharma& case manager will contact them to provide next steps for accessing treatment.
Eligibility Criteria
Eligibility Criteria
Patient Instructions
If you are an eligible, commercially insured patient, the RUBRACA co-pay card will reduce your out-of-pocket costs up to the copay program annual limitation. If you reach the maximum annual limit, you will be responsible for any additional cost.
When you use this card, you are certifying that you understand and agree to comply with the program Terms & Conditions below.
Terms & Conditions
Eligibility Criteria
Household Size | Annual Income* |
---|---|
1 | $45,180 or less |
2 | $61,320 or less |
3 | $77,460 or less |
4 | $93,600 or less |
If your household has more than four members, please add $16,140* for each additional dependent member. |
Terms & Conditions
These Terms & Conditions are effective as of 01/01/2025.
Personal progress tracking to help set and keep goals
Comprehensive information in a simple, digestible format
New weekly information to help change habits step by step
Lessons are completed at the pace of the user, and patients are able to download and print lessons to keep with them as they control their own progress.
RUBRACA® (rucaparib) is indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA.
In ARIEL3, of patients with a germline and/or somatic BRCA mutation treated with RUBRACA, MDS/AML occurred in 9 out of 129 (7%) patients treated with RUBRACA and 4 out of 66 (6%) patients treated with placebo. The duration of therapy with RUBRACA in patients who developed secondary MDS/cancer therapy-related AML varied from 1.2 to 4.7 years.
Most common adverse reactions of patients with BRCA-mutated mCRPC in TRITON2 (≥ 20%; Grade 1-4) were fatigue/asthenia (62%), nausea (52%), anemia (43%), AST/ALT elevation (33%), decreased appetite (28%), rash (27%), constipation (27%), thrombocytopenia (25%), vomiting (22%), and diarrhea (20%).